BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Teva Pharmaceutical Industries readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Teva Pharmaceutical Industries's 
 drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06568237-1679@assetmemo.bio
DTSTAMP:20261121T003117Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Emrusolmin: Phase 2 readout est. (NCT06568237)
DESCRIPTION:Emrusolmin\, phase 2.\nStudy: A Trial to Test if TEV-56286 is E
 ffective for Treatment of Participants With Multiple System Atrophy\nEstim
 ated primary completion: 15 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/emrusolmin#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06568237
URL:https://assetmemo.bio/drug/emrusolmin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184996-1@assetmemo.bio
DTSTAMP:20261121T003117Z
DTSTART;VALUE=DATE:20280509
DTEND;VALUE=DATE:20280510
SUMMARY:duvakitug: Phase 3 readout est. (NCT07184996)
DESCRIPTION:duvakitug\, phase 3\, Ulcerative Colitis.\nStudy: An Induction 
 Study to Investigate the Efficacy and Safety of Duvakitug in Participants 
 With Moderately to Severely Active Ulcerative Colitis\nEstimated primary c
 ompletion: 9 May 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/duvakitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07184996
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07812116-1@assetmemo.bio
DTSTAMP:20261121T003117Z
DTSTART;VALUE=DATE:20280616
DTEND;VALUE=DATE:20280617
SUMMARY:duvakitug: Phase 2 readout est. (NCT07812116)
DESCRIPTION:duvakitug\, phase 2\, Hidradenitis Suppurativa.\nStudy: A Study
  to Investigate Efficacy and Safety of Duvakitug in Adult Participants Wit
 h Moderate to Severe Hidradenitis Suppurativa\nEstimated primary completio
 n: 16 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/duva
 kitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07812116
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185009-1@assetmemo.bio
DTSTAMP:20261121T003117Z
DTSTART;VALUE=DATE:20280921
DTEND;VALUE=DATE:20280922
SUMMARY:duvakitug: Phase 3 readout est. (NCT07185009)
DESCRIPTION:duvakitug\, phase 3\, Ulcerative Colitis.\nStudy: A Maintenance
  Study to Investigate the Efficacy and Safety of Duvakitug in Participants
  With Moderately to Severely Active Ulcerative Colitis\nEstimated primary 
 completion: 21 September 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/duvakitug#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07185009
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07197866-1679@assetmemo.bio
DTSTAMP:20261121T003117Z
DTSTART;VALUE=DATE:20290503
DTEND;VALUE=DATE:20290504
SUMMARY:Emrusolmin: Phase 2 readout est. (NCT07197866)
DESCRIPTION:Emrusolmin\, phase 2.\nStudy: An Extension Trial to Test if TEV
 -56286 is Effective in Relieving Multiple System Atrophy\nEstimated primar
 y completion: 3 May 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/emrusolmin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07197866
URL:https://assetmemo.bio/drug/emrusolmin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184931-1@assetmemo.bio
DTSTAMP:20261121T003117Z
DTSTART;VALUE=DATE:20290514
DTEND;VALUE=DATE:20290515
SUMMARY:duvakitug: Phase 3 readout est. (NCT07184931)
DESCRIPTION:duvakitug\, phase 3\, Crohn's Disease.\nStudy: An Induction Stu
 dy to Investigate the Efficacy and Safety of Duvakitug in Participants Wit
 h Moderately to Severely Active Crohn's Disease\nEstimated primary complet
 ion: 14 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/duv
 akitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07184931
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184944-1@assetmemo.bio
DTSTAMP:20261121T003117Z
DTSTART;VALUE=DATE:20290813
DTEND;VALUE=DATE:20290814
SUMMARY:duvakitug: Phase 3 readout est. (NCT07184944)
DESCRIPTION:duvakitug\, phase 3\, Crohn's Disease.\nStudy: A Maintenance St
 udy to Investigate the Efficacy and Safety of Duvakitug in Participants Wi
 th Moderately to Severely Active Crohn's Disease\nEstimated primary comple
 tion: 13 August 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /duvakitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07184944
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
